Welcome to our dedicated page for Exicure SEC filings (Ticker: XCUR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Exicure, Inc. filings document a clinical-stage biotechnology issuer centered on burixafor (GPC-100) and hematologic disease development, along with the corporate governance and financing matters that support that operating structure. Its 8-K reports include financial results, liquidity disclosures, research and development expense trends, and clinical or regulatory events tied to the burixafor Phase 2 program and related license and collaboration arrangements.
Other filings record director and executive management changes, audit committee appointments, material agreements, shareholder voting matters, and capital-structure disclosures. Exicure's public records also describe intercompany financing activity involving KC Creation Co., Ltd. convertible bonds and the company's acquisition-related shift from its historical nucleic acid therapy platform to a hematologic-disease pipeline.
Exicure, Inc. reported significant leadership and board changes. On February 6, 2026, three directors — Andy Yoo, Seung Ik Baik, and Aejin Hwang — resigned from the Board effective February 9, 2026, with the company stating there were no disagreements over operations or policies.
The Board simultaneously appointed Jung Kyu Ham, Jung Soo Kim, and Gyeung Seog Cheon as new directors, with staggered terms through the 2026, 2027, and 2028 annual meetings, and named Mr. Cheon to the audit committee. Each new director will receive a $20,000 annual retainer.
The Board also approved a one-time $20,000 cash payment to each of the two remaining directors, Dongho Lee and Sangjin Yeo, and to outgoing director Hwang. On the same date, Yoo resigned as Chief Executive Officer and President, and Baik resigned as Chief Financial Officer and Secretary, effective February 9, 2026. The Board has not yet appointed successors, and Baik received a $150,000 separation payment.
Exicure, Inc. reported achieving the first contractual milestone under its License and Collaboration Agreement with GPCR Therapeutics Inc., tied to completing a Phase 2 clinical trial of its novel stem cell mobilizer (CXCR4 inhibitor Burixafor, GPC‑100). The milestone was reached when the Clinical Study Report was formally submitted to the U.S. Food and Drug Administration on January 16, 2026. Under the agreement, Exicure must pay $1,000,000 to GPCR Therapeutics within 30 days, and completion of this milestone also triggers a future sublicensing income‑sharing ratio that increases Exicure’s participation in the long‑term economics of the program.
Exicure HiTron Inc., a major shareholder of Exicure, Inc., has updated its ownership report after selling part of its stake. On January 21, 2026, Exicure HiTron completed a share transfer of 258,367 common shares at $4.50 per share, for total proceeds of $1,162,651.5. The shares were sold under share transfer agreements dated December 30, 2025 and were transferred to Jeon Sungchan for liquidity purposes.
After this transaction, Exicure HiTron reports beneficial ownership of 1,598,947 Exicure common shares, which represents about 25.1% of the company’s outstanding common stock. The ownership percentages are based on 6,373,869 shares outstanding as of November 3, 2025, as disclosed in Exicure’s Form 10-Q.
Exicure HiTron Inc., a more than 10% owner of Exicure, Inc. (XCUR), reported a sale of common stock. On 01/21/2026, the reporting person sold 258,367 shares of Exicure common stock at a price of $4.5 per share in an open-market transaction coded as "S" for sale.
After this transaction, Exicure HiTron Inc. beneficially owned 1,598,947 shares of Exicure common stock, held in direct ownership form. This filing is a routine Form 4 disclosure of insider activity and does not by itself describe any change to Exicure’s underlying business operations.
Exicure HiTron Inc. filed Amendment No. 4 to its Schedule 13D on Exicure, Inc., updating its ownership after a significant share transfer. On January 16, 2026, Exicure HiTron completed the transfer of 734,747 shares of Exicure common stock at $4.50 per share, for total proceeds of $3,306,361.5. The shares were transferred to Daolam Co., Ltd (246,913 shares), Lee So Jung (243,918 shares), and Kim Jun Sue (243,916 shares).
After these transfers, Exicure HiTron reports beneficial ownership of 1,857,314 shares of Exicure common stock, representing approximately 29.2% of the 6,373,869 shares outstanding as reported in Exicure’s Form 10-Q. The filing reflects updated ownership and transaction details but does not change Exicure HiTron’s status as a major shareholder.
Exicure HiTron Inc., a 10% owner of Exicure, Inc. (XCUR), reported an open market sale of 734,747 shares of common stock on January 16, 2026 at a price of $4.5 per share. After this transaction, Exicure HiTron Inc. beneficially owned 1,857,314 shares of Exicure common stock, held in direct ownership form.
Exicure HiTron Inc., a major shareholder of Exicure, Inc., has amended its beneficial ownership report after selling part of its stake. On January 7, 2026, Exicure HiTron completed share transfer agreements covering 741,272 common shares at $4.50 per share, for total proceeds of $3,335,724. The shares were sold for liquidity purposes to three individuals: Im Sung Jin, Lee Aram, and Im Bumjin.
After giving effect to these transfers, Exicure HiTron reports beneficial ownership of 2,592,061 Exicure common shares, representing about 40.7% of the 6,373,869 shares outstanding as of November 3, 2025. Exicure HiTron retains sole voting and dispositive power over these remaining shares.
Exicure HiTron Inc., a 10% owner of Exicure, Inc. (XCUR), reported a sale of common stock. On January 7, 2026, the entity sold 741,272 shares of Exicure common stock at a price of $4.50 per share, coded as an open-market or similar sale. After this transaction, Exicure HiTron Inc. beneficially owned 2,592,061 common shares, held directly.
Exicure, Inc. (XCUR) reported an insider equity transaction by its Chief Accounting Officer. On 11/16/2025, the officer had 7 shares of common stock withheld by Exicure to satisfy tax withholding obligations related to the vesting of restricted stock units. Following this withholding, the officer beneficially owns 309 shares of Exicure common stock in direct ownership form. This type of transaction does not involve an open-market buy or sell, but reflects routine share withholding tied to equity compensation.
Exicure, Inc. reported that on November 10, 2025 it redeemed in full 4.5 billion KRW (approximately $3.125 million) of 2.90% Convertible Bonds due 2028. These bonds were originally issued on April 30, 2025 by its wholly owned subsidiary KC Creation Co., Ltd. and were held entirely by Exicure, with no third-party holders involved. The redemption was funded through internal cash transfers as part of an effort to simplify intercompany financing and secure liquidity for ongoing biotechnology operations. Because this is an internal transaction between Exicure and its subsidiary, it will be eliminated in consolidation and is not expected to have a material impact on Exicure’s consolidated financial statements.